证券日报网讯 1月16日，高华科技在互动平台回答投资者提问时表示，公司始终重视国际化市场拓展， 欧洲是公司海外业务布局的重要关注区域之一，目前已有少量产品出口至欧洲市场，后续公司将持续跟 进海外市场动态，结合自身业务发展战略，稳步推进包括欧盟在内的海外市场开拓。若相关业务有重大 进展，公司将严格按照法律法规及交易所规定，及时履行信息披露义务。 （文章来源：证券日报） ...

Group 1: Company Restructuring and Financial Performance - The company is currently in the process of restructuring, having received an inquiry letter in July and completed the related responses by September. The restructuring report was revised and disclosed on November 11, 2025, and is still under review [1] - For the first three quarters of 2025, the company achieved operating revenue of 271.53 million yuan, a year-on-year increase of 25.79%. The net profit attributable to shareholders was 49.43 million yuan, up 81.48% year-on-year [9] Group 2: Gross Margin and Business Segments - The overall gross margin for the first three quarters has declined compared to 2024, primarily due to structural impacts from two business segments. The gross margin for cell culture products remains stable at 70%-71% [2] - The cell culture product segment generated revenue of 238.60 million yuan, reflecting a significant growth of 32.56% year-on-year, and remains the core revenue driver for the company [3] Group 3: Market Expansion and Client Engagement - The company is successfully engaging with multinational corporations (MNCs) in the U.S., with products being tested by several American pharmaceutical companies. There are over 10 pipelines associated with business development (BD) going overseas [5] - The company has established a U.S. research laboratory in 2024 and is considering building a production base in the U.S. to meet overseas client demands [5] Group 4: Product Pricing and Market Position - The company maintains strong customer loyalty in the antibody drug field, with long-term supply agreements that allow for differentiated pricing based on purchase volume [4] - According to a market research report, the company ranked first among domestic manufacturers of cell culture media for high-end antibody drugs in 2020, indicating a growing market share [8]

Core Viewpoint - The company aims to build a comprehensive R&D system by benchmarking against world-class vaccine enterprises through a diversified model of "independent research + external cooperation + technology introduction" [1] Group 1 - The company is actively promoting international market expansion [1] - The company is enriching its product pipeline and diversifying its business layout [1] - The company is enhancing brand value and facilitating global cooperation [1] Group 2 - The company seeks to improve international brand influence through coordinated efforts across the entire industry chain [1]